Exelixis thyroid cancer drug may get early approval
(Reuters) - Exelixis Inc's drug to treat a rare form of thyroid cancer met the main goal of a late-stage study, prompting the company to look to an accelerated approval process that could bring the...
View ArticleNovartis, Vectura lung drugs face delay in U.S.
LONDON (Reuters) - Two lung drugs being developed by Novartis and its British partner Vectura face delays in the United States, the Swiss drugmaker said on Tuesday, in an update with third-quarter...
View ArticleWorld Intellectual Property Organization holds an innovation consortium
GENEVA (Reuters) - The World Intellectual Property Organization launched a consortium on Wednesday that would allow the public and private sector to share intellectual property to promote the...
View ArticleBiogen MS drug BG-12 meets goal of second trial
By Toni Clarke (Reuters) - Biogen Idec Inc's said on Wednesday its experimental multiple sclerosis drug BG-12 met the main goal of a closely watched clinical trial, sending its shares...
View ArticleMashups aren't just for dance parties; researchers combine 3D printing with...
Traditionally, drugs were discovered by identifying active ingredients in known remedies or through serendipitous discovery, such as penicillin. Currently, drug discovery focuses on understanding the...
View ArticleFDA approves Bayer/J&J's stroke drug Xarelto
(Reuters) - U.S. health regulators approved on Friday the stroke preventer Xarelto from Bayer AG and Johnson & Johnson for people with a common heart rhythm disorder known as atrial fibrillation....
View ArticleAblynx regains nanobody rights from Pfizer
BRUSSELS (Reuters) - Belgian biotech firm Ablynx said on Friday that it had regained the rights for its TNF-Alpha targeting nanobodies from Pfizer, which form the basis of a rheumatoid arthritis...
View ArticleMcKesson ExpressRx Track plan increases efficiency and prescription volume
McKesson High Volume Solutions will introduce ExpressRx Track this week in New Orleans at the 46th American Society of Health-system Pharmacists Midyear Clinical Meeting and Exhibition. The ExpressRx...
View ArticlePredicting adverse drug reactions
Researchers at Children’s Hospital Boston have created a new mathematical model that combines multiple forms of widely available data to predict adverse drug events (ADEs). This new method may be able...
View ArticleSilk microneedles painlessly deliver controlled-release drugs
Bioengineers at Tufts University School of Engineering have developed a silk-based microneedle able to deliver precise drug amounts over a set time. In addition, these new silk microneedles inhibited...
View ArticleNanoparticles could deliver drugs to the brain
Researchers at the University of Buffalo (UB) have released results indicating that ORMOSIL (organically modified silica) nanoparticles could be used to deliver drugs. Each nanoparticle is a vessel,...
View ArticlePutting the brakes on cocaine addiction
Researchers have discovered a brain mechanism that limits the rewarding sensations of cocaine. Recent research with rodents implicated histone deacetylases (HDACs), which are modulators of gene...
View ArticleResearchers develop new mechanism of drug release over an extended period
Researchers at Brigham and Women’s Hospital in Boston, Mass. have developed a new mechanism of drug release. It uses 3D superhydrophobic materials that make use of air as a removable barrier, which...
View ArticleDrugs: 'New' does not always mean 'better'
Cases in which a newly approved drug is more effective than the cheaper alternatives already available are the exceptions rather than the rule. This is the conclusion reached in new study in the...
View ArticleNew process could make malaria drug less costly
Scientists have developed a process that would make the most effective anti-malarial treatment less costly. The new technique makes it easier to produce artemisinin combination therapy (ACT) which...
View ArticleState Department, Universities Blast UN Attack on Patents
If the UN Secretary General and the members of his “High Level Panel on Access to Medicines” thought the State Department was bluffing when it warned against their attempt to make intellectual...
View ArticleVanda v. Roxane Labs. – Are Two Natural Laws Better Than One?
As you will recall, in Prometheus v. Mayo, the Supreme Court held that a claim reciting a natural law had to have other non-conventional steps to pass muster under s. 101. The natural law in Mayo was...
View ArticleWinning the Drug Development Debate
The stage is being set for a coordinated attack on the patent system under the guise of making international health care more affordable. A newly released United Nations report encourages developing...
View ArticlePatexia Insight 112: ANDA Litigation is Declining
A couple of weeks ago we released our second annual ANDA Litigation Intelligence Report where we covered the rankings, statistics, and comprehensive analysis of ANDA and Hatch-Waxman stakeholders. We...
View ArticleHow Do Patents Affect The Healthcare Industry?
Global health care spending is predicted to reach $10 trillion USD during 2022 with almost 30% of it belonging to the USA. It might sound like a good industry to be in, but keep in mind that the costs...
View Article